AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

QoL improvements were also significant, as assessed by the Schizophrenia Quality ... and was first approved by the US Food and Drug Administration (FDA) in 2009. It is marketed by Eli Lilly ...

which the U.S. Food and Drug Administration approved for the treatment of schizophrenia in September 2024. (Bristol Myers Squibb via AP) This image provided by Bristol Myers Squibb in October 2024 ...

which the U.S. Food and Drug Administration approved for the treatment of schizophrenia in September 2024. (Bristol Myers Squibb via AP) There’s been great hope among doctors for Cobenfy ...

The Food and Drug Administration approved Cobenfy on the ... “It’s not any higher or any lower than what we typically see” in schizophrenia studies, said Dr. Greg Mattingly of Washington ...